comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 10:59:13 - browse：152

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Physician groups backed by private equity giant lobby on mergers

WSS

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Amazon expands telehealth clinic nationwide

Lawsuit alleges UnitedHealth Group unit illegally denied claims

‘Oppenheimer’ and the risks of AI in health care

Physician groups backed by private equity giant lobby on mergers

Medicare Advantage enrollment hits roughly 33.4 million

knowledge

comprehensive

knowledge

How to save PrEP access — and even expand it

What the US credit downgrade means for the economy, your finances

Anesthesiologist group: stop taking Ozempic before surgery

New safety details link Apellis eye drug to rare cases of blindness

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Jerome Adams on the need for new antivirals for Covid

National panel will explore requiring free Covid tests

The cancer drug shortage isn’t new — and neither are the solutions

Obamacare plans could cover weight loss drugs

explore

Researchers tackle phage therapy hurdles for wider adoption

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Medicare Advantage enrollment hits roughly 33.4 million

Physician groups backed by private equity giant lobby on mergers

Sage hopes for a blockbuster in antidepressant now before FDA

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

knowledge

hotspot

focus

hotspot